Medico Remedies Ltd

Medico Remedies Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 26 August 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 11 September 2026, providing investors with the latest insights into the company's performance and outlook.

Medico Remedies Ltd has witnessed a notable shift in its valuation parameters, moving from a fair to an attractive rating, signalling a potential investment opportunity in the Pharmaceuticals & Biotechnology micro-cap segment. This change comes amid a challenging market backdrop and relative valuation pressures from its peers, prompting a reassessment of its price-to-earnings and price-to-book value multiples.

Medico Remedies Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating upgraded from Sell to Hold as of 26 August 2026. This shift reflects a nuanced reassessment across four key parameters: quality, valuation, financial trend, and technicals. While the company demonstrates improving fundamentals and attractive valuation metrics, technical indicators remain mixed, warranting a cautious stance for investors.

Medico Remedies Ltd has seen a notable shift in its valuation parameters, moving from a fair to an attractive rating despite ongoing sector headwinds. With a current price of ₹41.67 and a micro-cap market classification, the pharmaceutical company’s price-to-earnings (P/E) and price-to-book value (P/BV) ratios now present a more compelling investment case relative to its historical averages and peer group.

Medico Remedies Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 28 July 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 20 August 2026, providing investors with the latest insights into the company’s performance and outlook.

Medico Remedies Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 28 July 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 09 August 2026, providing investors with the latest insights into the company’s performance and outlook.

Medico Remedies Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating upgraded from Sell to Hold as of 28 July 2026. This change reflects a nuanced improvement across technical indicators, financial trends, valuation metrics, and overall company quality, signalling a cautious but more optimistic outlook for investors.

Medico Remedies Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 07 July 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 19 July 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

Medico Remedies Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Hold to Sell as of 7 July 2026. This shift reflects a combination of deteriorating technical indicators, subdued long-term growth prospects, and mixed financial performance despite recent quarterly improvements. The company’s Mojo Score now stands at 47.0, signalling caution for investors amid a challenging market backdrop.

Medico Remedies Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating upgraded from Sell to Hold as of 2 July 2026. This change reflects a nuanced improvement across technical indicators, valuation metrics, financial trends, and overall quality assessments, signalling a cautious but positive outlook for investors.

Medico Remedies Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has been downgraded from a Hold to a Sell rating by MarketsMOJO as of 23 June 2026. This change reflects a deterioration in technical indicators alongside concerns over the company’s long-term growth prospects despite recent positive quarterly financial results.

Medico Remedies Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating upgraded from Sell to Hold as of 16 June 2026. This change reflects a nuanced improvement across technical indicators, financial performance, valuation metrics, and overall quality assessments, signalling a cautious but positive outlook for investors.

Medico Remedies Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Hold to Sell as of 11 June 2026. This shift reflects a combination of deteriorating technical indicators, tempered long-term growth prospects, and valuation concerns despite recent positive quarterly financial results.

Medico Remedies Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 04 May 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 01 June 2026, providing investors with an up-to-date perspective on the company’s performance and outlook.

Medico Remedies Ltd., a micro-cap pharmaceutical manufacturer, delivered a robust performance in Q4 FY26 (January-March 2026) with net profit surging 35.02% year-on-year to ₹5.86 crores, marking the company's strongest quarterly earnings to date. However, the quarter-on-quarter decline of 3.19% in revenue and persistent margin volatility have raised questions about the sustainability of this growth trajectory for the ₹389.69 crore market capitalisation company.

Medico Remedies Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 04 May 2026. While the rating change occurred on that date, the analysis and financial metrics discussed here reflect the stock's current position as of 21 May 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.